Insights
Search Results
Client Highlights
4.09.26
Wilson Sonsini Advises Forte Biosciences on $150 Million Public Offering
On April 8, 2026, Forte Biosciences, Inc., a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, announced the pricing of a public offering of 5,709,936 shares of its common stock at a price to the public of $26.27 per share. The gross proceeds from the offering are expected to be approximately $150 million before deducting underwriting discounts and commissions and other offering expenses. Wilson Sonsini Goodrich & Rosati advised Forte Biosciences on the transaction.
Client Highlights
4.02.26
Wilson Sonsini Advises View Point Medical on Acquisition by Merit Medical
On April 1, 2026, Merit Medical Systems, Inc., a global leader of healthcare technology, announced it has acquired View Point Medical, Inc. The aggregate transaction consideration, including the assumption of View Point liabilities, is approximately $140 million. Wilson Sonsini Goodrich & Rosati advised View Point on the transaction.
Client Highlights
2.05.26
Wilson Sonsini Advises SpyGlass Pharma on $150 Million IPO
On February 5, 2026, SpyGlass Pharma, Inc., a late-stage biopharmaceutical company, announced the pricing of its initial public offering of 9,375,000 shares of its common stock at a public offering price of $16.00 per share. The aggregate gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by SpyGlass Pharma, are expected to be approximately $150 million. Wilson Sonsini Goodrich & Rosati advised SpyGlass Pharma on the transaction.
SpyGlass Pharma has granted the underwriters a 30-day option to purchase up to an additional 1,406,250 shares of common stock at the initial public offering price, less underwriting discounts and commissions. All shares of common stock are being offered by SpyGlass Pharma. SpyGlass Pharma’s common stock is expected to begin trading on the Nasdaq Global Select Market on February 6, 2026, under the ticker symbol “SGP.” The offering is expected to close on February 9, 2026, subject to the satisfaction of customary closing conditions.
The Wilson Sonsini team that advised SpyGlass Pharma includes:
SpyGlass Pharma has granted the underwriters a 30-day option to purchase up to an additional 1,406,250 shares of common stock at the initial public offering price, less underwriting discounts and commissions. All shares of common stock are being offered by SpyGlass Pharma. SpyGlass Pharma’s common stock is expected to begin trading on the Nasdaq Global Select Market on February 6, 2026, under the ticker symbol “SGP.” The offering is expected to close on February 9, 2026, subject to the satisfaction of customary closing conditions.
The Wilson Sonsini team that advised SpyGlass Pharma includes:
Client Highlights
8.01.25
Firm Advises LENZ Therapeutics in Matters Related to FDA’s Approval of VIZZ
On July 31, 2025, LENZ Therapeutics announced that the U.S. Food and Drug Administration (FDA) has approved VIZZ (aceclidine ophthalmic solution) 1.44 percent, making it the first and only aceclidine-based eye drop approved to improve near vision in adults with presbyopia. Wilson Sonsini Goodrich & Rosati serves as outside general counsel for LENZ and advised the company on general corporate and IP matters related to the FDA’s approval of VIZZ.
Samples of VIZZ are anticipated in the United States as early as October 2025, with commercial product to be broadly available by mid-Q4 2025. Direct-to-eye care professional sales and marketing activities will be initiated immediately. Aceclidine, the sole active ingredient in VIZZ, is a new chemical entity in the United States and its FDA approval marks a global first in the treatment of presbyopia, a condition that impacts approximately 128 million adults in the U.S.
The Wilson Sonsini team advising LENZ was led by Dan Koeppen, Ben Capps, Mike Hostetler, and Ian Edvalson.
For more information, please see LENZ Therapeutics’ news release and visit www.VIZZ.com.
Samples of VIZZ are anticipated in the United States as early as October 2025, with commercial product to be broadly available by mid-Q4 2025. Direct-to-eye care professional sales and marketing activities will be initiated immediately. Aceclidine, the sole active ingredient in VIZZ, is a new chemical entity in the United States and its FDA approval marks a global first in the treatment of presbyopia, a condition that impacts approximately 128 million adults in the U.S.
The Wilson Sonsini team advising LENZ was led by Dan Koeppen, Ben Capps, Mike Hostetler, and Ian Edvalson.
For more information, please see LENZ Therapeutics’ news release and visit www.VIZZ.com.
Client Highlights
7.30.25
Wilson Sonsini Advises ImmunityBio on Execution of $80 Million Equity Financing
On July 25, 2025, ImmunityBio, a biotechnology company developing therapies that bolster the natural immune system to defeat cancers and infectious diseases, announced it has executed financing to provide further working capital and support its ongoing business operations. The company entered into a securities purchase agreement for a registered direct offering with two institutional investors, providing for the issuance of common stock of ImmunityBio as well as warrants for the purchase of additional shares of common stock of ImmunityBio that is expected to result in gross proceeds at closing of approximately $80 million before deducting placement agent fees and other offering-related expenses, subject to customary closing conditions. If fully exercised, the warrants could result in additional gross proceeds of up to approximately $96 million. Wilson Sonsini Goodrich & Rosati advised ImmunityBio on the transaction.
The Wilson Sonsini team advising ImmunityBio includes:
Corporate
Patents and Innovations
For more information, please see ImmunityBio’s press release.
Client Highlights
7.01.25
Wilson Sonsini Advises Celltrio on $15 Million Financial Investment
On June 17, 2025, Celltrio, a pioneering life sciences company delivering advanced automation solutions for cell culturing and cell and gene therapy, announced the closing of a $15 million financial investment round led by Premier Partners, a leading investor in healthcare innovation. Wilson Sonsini Goodrich & Rosati advised Celltrio on the transaction.
The new funding will accelerate the global commercialization of RoboCell®, Celltrio’s flagship modular platform for fully automated, sterile cell culturing and cell therapy manufacturing. Investment proceeds will be used to scale manufacturing capabilities; expand commercial operations across North America, Europe, and Asia; and fuel continued innovation of GMP-ready automation solutions for biopharma, regenerative medicine, and advanced research laboratories.
The Wilson Sonsini team that advised Celltrio on the transaction included:
Corporate
Ben Capps
Dani Glazer Signaigo
James Keegan
Regulatory
Nimit Dhir
Jahna Hartwig
For more information, please see Celltrio’s news release.
The new funding will accelerate the global commercialization of RoboCell®, Celltrio’s flagship modular platform for fully automated, sterile cell culturing and cell therapy manufacturing. Investment proceeds will be used to scale manufacturing capabilities; expand commercial operations across North America, Europe, and Asia; and fuel continued innovation of GMP-ready automation solutions for biopharma, regenerative medicine, and advanced research laboratories.
The Wilson Sonsini team that advised Celltrio on the transaction included:
Corporate
Ben Capps
Dani Glazer Signaigo
James Keegan
Regulatory
Nimit Dhir
Jahna Hartwig
For more information, please see Celltrio’s news release.
Client Highlights
6.25.25
Firm Advises Forte Biosciences on $75 Million Public Offering
On June 24, 2025, Forte Biosciences, Inc., a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, announced the pricing of a public offering of shares of its common stock and pre-funded warrants at a price to the public of $12.00 per share. Wilson Sonsini Goodrich & Rosati advised Forte on the transaction. The gross proceeds from the offering are expected to be approximately $75 million before deducting underwriting discounts and commissions and other offering expenses. The offering is expected to close on or about June 26, 2025, subject to satisfaction of customary closing conditions.
Client Highlights
11.21.24
Wilson Sonsini Advises Forte Biosciences on Oversubscribed $53 Million Equity Financing
On November 20, 2024, biopharmaceutical company Forte Biosciences announced an oversubscribed $53 million equity financing to support the continuing clinical advancement of FB102, which is a proprietary anti-CD122 monoclonal antibody therapeutic candidate with potentially broad autoimmune and autoimmune-related indications. TD Cowen acted as the lead placement agent for the financing. Guggenheim Securities provided Capital Markets Advisory services to Forte Biosciences. Chardan, Rodman & Renshaw and Brookline Capital Markets acted as co-placement managers for the financing.
Press Releases
11.15.24
Wilson Sonsini Goodrich & Rosati Elects 16 New Partners
Contact:
Kimberly Brooks
Wilson Sonsini
+1 212.453.2881
kbrooks@wsgr.com
Kimberly Brooks
Wilson Sonsini
+1 212.453.2881
kbrooks@wsgr.com
Client Highlights
7.15.24
Wilson Sonsini Advises LENZ Therapeutics on $30 Million Private Placement Financing
On July 15, 2024, LENZ Therapeutics (LENZ), a late clinical-stage biopharmaceutical company focused on developing the first aceclidine-based eye drop to improve near vision in people with presbyopia, announced that it has entered into a stock purchase agreement with Ridgeback Capital for a $30 million private investment in public equity (PIPE) common stock financing. Wilson Sonsini Goodrich & Rosati advised LENZ on the transaction.
Client Highlights
3.21.24
Wilson Sonsini Advises LENZ Therapeutics on Completed Merger with Graphite Bio
On March 21, 2024, LENZ Therapeutics, Inc., a late clinical-stage biopharmaceutical company focused on developing the first aceclidine-based eye drop that has been shown to improve near vision in people with presbyopia, announced the completion of its previously announced merger with Graphite Bio, Inc. The new combined company will operate under the name LENZ Therapeutics, Inc. and will commence trading on Nasdaq under the ticker symbol “LENZ” on March 22, 2024. Wilson Sonsini Goodrich & Rosati advised LENZ Therapeutics on the transaction.
Client Highlights
11.15.23
Wilson Sonsini Represents LENZ Therapeutics in Merger with Graphite Bio
On November 15, 2023, LENZ Therapeutics, a late-stage biopharmaceutical company focused on developing and commercializing innovative therapies to improve vision, and Graphite Bio, Inc. announced that they have entered into a definitive merger agreement to combine the companies in an all-stock transaction. The lead programs of the combined company will address presbyopia, the inevitable loss of near vision that impacts the daily lives of nearly all people over the age of 45. The combined company is expected to trade on Nasdaq under the ticker symbol “LENZ.” Wilson Sonsini Goodrich & Rosati is representing LENZ Therapeutics in the transaction.